文献速递湿疹皮炎与荨麻疹

吡美莫司治疗特应性皮炎5年随机试验的安全性及有效性批判性评价

A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal.
PubMed 文献 · Br J Dermatol · 2017-09-04

本文对PETITE研究进行批判性评价,该研究为5年、药企资助的开放标签平行组随机试验,纳入3至12月龄轻中度特应性皮炎患儿,比较1%吡美莫司乳膏与外用糖皮质激素。

要点

  • 吡美莫司组支气管炎、感染性湿疹、脓疱疮和鼻咽炎发生率显著高于外用糖皮质激素组。

核心结论

  • PETITE研究结论认为外用糖皮质激素和吡美莫司长期治疗儿童轻中度特应性皮炎均安全,吡美莫司疗效与外用糖皮质激素相似,并支持吡美莫司作为儿童轻中度特应性皮炎的一线治疗。

研究设计与样本

  • 纳入3月龄及以上至12月龄以下轻中度特应性皮炎婴儿,按1:1比例随机分配接受1%吡美莫司乳膏或低至中效外用糖皮质激素霜/软膏治疗5年。

关键数值与推荐

  • 主要结局为具有主要临床关注的不良事件及任一组粗发生率≥5%的不良事件发生率。
  • 次要结局为长期疗效,定义为第3周和第5年时IGA≤1。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The PETITE study (Sigurgeirsson et al.) aimed to compare safety and efficacy of pimecrolimus 1% cream (PIM) and low-to-medium-potency topical corticosteroids (TCS) in children with mild-to-moderate atopic dermatitis (AD). SETTING AND DESIGN: Participants of this 5-year drug-company sponsored multicentre, open-label, parallel-group trial were recruited between April 2004 and October 2005. No details are reported regarding the study sites. STUDY EXPOSURE: Infants aged ≥ 3 to < 12 months with mild-to-moderate AD were randomly assigned in a 1 : 1 ratio to receive either PIM or a low- or medium-potency TCS cream/ointment for 5 years. No information on specific TCS products used was provided. The topical treatment was applied twice daily 'until complete AD clearance or for as long as allowed by the label of the specific TCS', and was reinitiated at the occurrence of first signs and symptoms of AD flares. In the PIM group, exacerbations not controlled by PIM were treated with short-term TCSs. OUTCOMES: Adverse events (AEs) and serious AEs (SAEs) were recorded 'during clinic visits'. In a proportion of the patients, various immunological assessments including antibody titres to common vaccine antigens, immunoglobulin levels, B and T lymphocyte cell counts, and T-cell proliferation tests were performed. The children's growth was assessed by measuring height and weight. AD severity was measured using the Investigator Global Assessment (IGA) score and the percentage of the total body surface area affected. No specific information was provided on the number and scheduling of study visits. Primary outcomes were the incidence of AEs 'of primary clinical interest' and those with a crude incidence of ≥ 5% in either treatment group. Secondary outcome was 'long-term efficacy' defined as IGA ≤ 1 at week 3 and year 5. RESULTS: Patients in the PIM group experienced significantly more AEs [bronchitis (P = 0·02), infected eczema (P ≤ 0·001), impetigo (P = 0·045), nasopharyngitis (P = 0·04)]. No significant differences were seen for the other AEs. The overall incidence of SAEs was slightly higher for PIM (20·5% vs. 17·3%; P = 0·046). The proportion of participants with IGA ≤ 1 at year 5 was 88·7% for PIM and 92·3% for TCS, a success rate difference of 3·6% (95% confidence interval 0·8-6·4) favouring TCS. CONCLUSIONS: Sigurgeirsson et al. conclude that the long-term management of mild-to-moderate AD in children with both TCS and PIM is safe, and that PIM has similar efficacy to TCS. Further, they conclude that their data support the use of PIM as a first-line treatment of mild-to-moderate AD in children.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Weidinger S, Baurecht H, Schmitt J, et al. A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal. Br J Dermatol. 2017. PMID: 28868633. doi:10.1111/bjd.15827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。